NNNN · NASDAQ
Anbio Biotechnology (NNNN) Stock Price & Fundamentals
Anbio Biotechnology (NNNN) closed at $945.09 on Oct 9, 2026, down 0.53% from the previous close of $950.13.
Share price, past year
1Y +42.27%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $945.09 |
| Sep 30, 2026 | $928.58 |
| Aug 31, 2026 | $888.04 |
| Jul 31, 2026 | $863.36 |
| Jun 30, 2026 | $819.82 |
| May 29, 2026 | $769.35 |
| Apr 30, 2026 | $754.99 |
| Mar 31, 2026 | $765.31 |
| Feb 27, 2026 | $769.13 |
| Jan 30, 2026 | $755.96 |
| Dec 31, 2025 | $719.40 |
| Nov 28, 2025 | $721.53 |
| Oct 31, 2025 | $720.34 |
Key statistics
- Market cap
- —
- P/E (TTM)
- —
- EPS (TTM)
- —
- Revenue (TTM)
- —
- Net income (TTM)
- —
- Shares outstanding
- —
- Dividend yield
- —
- 52-week range
- $664.30 – $950.13
Financials
Anbio Biotechnology reported revenue of $8.65M for fiscal 2025, up 5.64% from fiscal 2024.
Anbio Biotechnology earned net income of $6.40M in fiscal 2025, a net margin of 74.1%.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $8.65M | +5.6% | $6.40M | 74.1% | $0.147 | — |
| FY2024ended Dec 31, 2024 | $8.19M | +22.0% | $2.37M | 29.0% | $0.056 | — |
| FY2023ended Dec 31, 2023 | $6.71M | −71.5% | $2.25M | 33.6% | $0.105 | — |
| FY2022ended Dec 31, 2022 | $23.54M | — | $10.01M | 42.5% | $100,112.00 | — |
Company profile
- Name
- Anbio Biotechnology
- Ticker
- NNNN
- Exchange
- NASDAQ
- Industry (SEC SIC)
- In Vitro & In Vivo Diagnostic Substances
- Headquarters
- Friedrich-Ebert-Anlage 49, Frankfurt Am Main, 2M 60308
- Incorporated in
- E9
- Fiscal year ends
- December
- SEC CIK
- 0001982708
Frequently asked questions
What is Anbio Biotechnology's stock price?
Anbio Biotechnology (NNNN) closed at $945.09 on Oct 9, 2026, down 0.53% from the previous close of $950.13.
How much revenue does Anbio Biotechnology make?
Anbio Biotechnology reported revenue of $8.65M for fiscal 2025, up 5.64% from fiscal 2024.
Sources and methodology
Fundamentals come from Anbio Biotechnology's filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures